维生素B12调节D-银糖诱导的功能障碍
M Nagaraju1, Krishna Kalyan Kalahasti1, Udaykanth Suryavanshi1
1Department of Biochemistry, ICMR National Institute of Nutrition, Hyderabad, Telangana, India.
The Indian journal of medical research
|October 16, 2025
概括
维生素B12补充剂有助于通过减少细胞衰老和氧化应激来管理与年龄相关的功能障碍. 这项研究表明,维生素B12可以缓解损伤标志物,并改善老年老鼠的功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 老年学是一门学科.
- 生物化学 生化学
背景情况:
- 与年龄相关的功能障碍是一个日益严重的临床问题.
- 细胞衰老和氧化应激是与年龄相关的慢性病 (CKD) 的关键驱动因素.
- 诸如高级糖化终产物 (AGEs) 和高酸血等因素加速衰老和功能障碍.
研究的目的:
- 研究维生素B12对与年龄相关的功能障碍的保护作用.
- 阐明维生素B12在减轻脏衰老中的潜在机制.
- 评估维生素B12对衰老,炎症,纤维化和衰老的影响.
主要方法:
- 使用D-银糖诱导衰老的老鼠模型.
- 服用维生素B12以评估其对功能和损伤标志物的影响.
- 分析了与衰老,代谢,炎症,纤维化和亡有关的信号通路,使用qRT-PCR和免疫阻塞.
主要成果:
- 维生素B12补充剂减轻了功能障碍,并缓解了老化引起的AGE积累和高酸血症.
- 它通过调节RAGE-NFkB,pPERK-GSK3β和JNK信号通路来减少炎症,纤维化和亡.
- 维生素B12通过Klotho-FGF23轴减轻过酸血症.
结论:
- 维生素B12在治疗与年龄相关的功能障碍方面具有显著的潜力.
- 这些发现支持维生素B12作为一种治疗策略,以保持老年人功能.
- 机制包括调节衰老,酸盐稳定和炎症/纤维细胞通路.
更多相关视频
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
610
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
916
相关概念视频
01:11Renal Failure: Dose Adjustments
434
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
434
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249
01:30Vitamins
2.3K
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.3K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207
01:27Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
01:24Chronic Kidney Disease II: Clinical Manifestations
547
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
547